

09 Feb 2024 | Interviews

# Diagnostics CEOs In Triplicate Weigh In On Upcoming Hurdles

by Barnaby Pickering

Tune in to this one-off podcast feature discussing the state-of-play in the diagnostics sector, with guests from ImmunExpress, Lucid Diagnostics and ChromaCode.

During this podcast, *Medtech Insight* speaks to Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis; Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer; and Lishan Aklog, CEO of Lucid Diagnostics, who developed a cell-collection method that aims to bring forward the stage at which esophageal cancer can be diagnosed.

The trio discuss the companies' products and why they are transformative, as well as the upcoming regulatory and commercial hurdles awaiting diagnostics companies.

## Timestamps:

- 1:25. Introductions from Rollie Carlson, Lishan Aklog and Mark McDonough
- 5:40. Recent company updates from ImmunExpress and Lucid Diagnostics
- 8:30. False positives, false negatives – their importance in different diagnostic applications
- 16:17. Broad commercial themes for 2024
- 22:40. The raw deal that diagnostics receives – what's going on with pricing?
- 32:00. LDT rule change – who is it good for, and who is it bad for?
- 41:10. 2024 – anything to look forward to?

Listen to the podcast via the player below:

[Click here to explore this interactive content online](#) 